Do GH Peptides Improve Strength and Power?

IGF-1 and Muscle

+1.1 kg lean mass

MK-677 increased fat-free mass in healthy older adults over 12 months, yet isokinetic strength did not change.

Nass et al., Annals of Internal Medicine, 2008

Nass et al., Annals of Internal Medicine, 2008

View as image

Growth hormone peptides reliably increase GH, IGF-1, and lean body mass. That much is clear from decades of clinical trials. The assumption that follows is straightforward: more lean mass should mean more strength and power. But as the research on IGF-1 and muscle makes clear, the relationship between growth factors and functional muscle performance is far less direct than most people expect. The largest and longest MK-677 trial ever conducted found zero improvement in strength despite significant lean mass gains over two years.^[1] That result captures the central tension in GH peptide research: hormonal elevation and body composition changes are real, but their translation to physical performance remains unproven.

The GH-Strength Assumption

The logic seems airtight. GH peptides stimulate pituitary GH release. GH triggers hepatic IGF-1 production. IGF-1 activates muscle protein synthesis pathways including mTOR and PI3K/Akt. Protein synthesis builds muscle. Muscle produces force. Therefore, GH peptides should increase strength.

Each link in that chain has supporting evidence. GH secretagogues promote pulsatile GH release subject to normal negative feedback, avoiding the supraphysiological spikes caused by exogenous GH injections.^[2] The resulting IGF-1 elevation is well documented across multiple peptide classes. And IGF-1 does participate in skeletal muscle hypertrophy through both autocrine and endocrine signaling.

But the chain breaks at the final link. Elevating GH and IGF-1 through peptides consistently changes body composition without consistently changing what that body can do. Understanding why requires examining what GH peptides actually deliver at each step.

What GH Peptides Do to Hormone Levels

The hormonal effects of GH secretagogues are among the best-documented outcomes in peptide research.

CJC-1295, a long-acting GHRH analog, produced some of the most dramatic results. A single subcutaneous injection in healthy adults aged 21 to 61 raised mean plasma GH concentrations 2 to 10-fold for six or more days and IGF-1 levels 1.5 to 3-fold for 9 to 11 days.^[3] Multiple doses showed cumulative effects, with IGF-1 remaining above baseline for up to 28 days. A follow-up study confirmed that CJC-1295 preserved normal GH pulsatility while increasing trough GH levels 7.5-fold and mean GH 46%.^[4] This pulsatile pattern matters because continuous GH exposure desensitizes receptors, while pulsatile release maintains downstream signaling. CJC-1295 also altered serum protein profiles in ways consistent with GH/IGF-1 axis activation, including changes in proteins involved in lipid metabolism and tissue remodeling.^[5]

MK-677 (ibutamoren), an oral ghrelin mimetic, provides the longest-duration data. In a two-year double-blind RCT with 65 healthy older adults (ages 60 to 81), daily 25 mg doses raised GH and IGF-1 to levels typical of healthy young adults.^[1] In obese males, eight weeks of MK-677 increased 24-hour GH secretion 1.8-fold and IGF-1 approximately 40%.^[6]

Ipamorelin demonstrated GH-releasing potency comparable to GHRP-6 in both animal models and human subjects, with one distinction that set it apart: it did not increase ACTH, cortisol, or prolactin even at doses 200 times higher than the effective GH-releasing dose.^[7] This selectivity made ipamorelin the first GH secretagogue that stimulated growth hormone without triggering stress hormone release, a limitation of older compounds like GHRP-2 and GHRP-6.

The hormonal effects are consistent and reproducible. GH peptides raise GH. GH raises IGF-1. The question is what happens next.

Lean Mass Gains: What the Numbers Show

Across multiple trials, GH peptide-driven lean mass gains range from roughly 1 to 3 kg over treatment periods of 8 weeks to 2 years.

The Nass et al. two-year MK-677 trial is the most rigorous dataset. Fat-free mass decreased 0.5 kg in the placebo group but increased 1.1 kg in the MK-677 group (P < 0.001). Body cell mass, measured by intracellular water, also increased: +0.8 kg in the MK-677 group versus -1.0 kg with placebo.^[1] The distinction between fat-free mass and body cell mass is critical and will be revisited below.

In obese males, Svensson et al. found that eight weeks of MK-677 produced a statistically significant increase in fat-free mass measured by both DEXA and a four-compartment body composition model, with an estimated gain of approximately 3 kg. Basal metabolic rate also increased at two weeks, though this effect was transient.^[6]

Under catabolic conditions, MK-677 reversed the protein breakdown caused by caloric restriction. Murphy et al. showed that in calorie-restricted healthy volunteers, MK-677 shifted daily nitrogen balance from -1.48 g/day (placebo) to +0.31 g/day (treatment), with IGF-1 increasing approximately 40%.^[8] This anti-catabolic effect, demonstrated in just seven days, is among the clearest functional outcomes from any GH peptide trial.

These lean mass changes are real and measurable. They appear across different populations (young, elderly, obese), different peptides (MK-677, CJC-1295), and different measurement methods (DEXA, four-compartment models, nitrogen balance). The evidence for GH peptides building muscle mass is stronger than many other peptide claims. But lean mass and functional strength are different measurements with different implications.

The Critical Gap: Lean Mass Without Strength

This is where expectations diverge from evidence.

The Nass et al. MK-677 trial measured isokinetic strength as a secondary endpoint throughout the two-year study period. Despite the 1.1 kg gain in fat-free mass and the 0.8 kg gain in body cell mass, there were no significant differences in strength between the MK-677 and placebo groups at any time point.^[1] The study authors explicitly noted: "Increased fat-free mass did not result in changes in strength or function."

This finding aligns with the broader GH literature. A 2008 systematic review in the Annals of Internal Medicine analyzed 27 studies of GH administration in 440 participants. Lean body mass increased by an average of 2.1 kg in GH recipients. Strength did not improve. Exercise capacity did not improve. The review concluded that claims of GH enhancing physical performance "are not supported by the scientific literature" (Liu et al., 2008). A subsequent 2017 meta-analysis of placebo-controlled trials in healthy young adults confirmed these findings: GH altered body composition without increasing muscle strength or aerobic exercise capacity (Meinhardt et al., 2017).

One partial exception exists. Some data suggest GH may improve anaerobic exercise capacity, meaning short-burst, high-intensity efforts like sprinting. This effect was observed in the 2017 meta-analysis and may involve metabolic changes (increased lactate clearance, enhanced glycolytic capacity) rather than structural muscle adaptations. Whether GH peptides specifically replicate this anaerobic benefit has not been directly tested.

Why Lean Mass Does Not Equal Strength

The disconnect between lean mass gains and strength gains has a physiological explanation. "Fat-free mass" as measured by DEXA or bioimpedance includes everything that is not adipose tissue: skeletal muscle, connective tissue, bone, organ tissue, and water. GH-axis stimulation affects several of these compartments simultaneously.

Extracellular water retention is a well-documented effect of GH elevation. GH promotes sodium and water retention through direct renal effects and through IGF-1-mediated mechanisms. In the Nass et al. trial, the increase in fat-free mass (1.1 kg) exceeded the increase in body cell mass (0.8 kg), suggesting that approximately 0.3 kg of the lean mass gain was extracellular water rather than cellular tissue.^[1] Other GH studies have reported even larger discrepancies. Water adds weight to the "lean" column on a DEXA scan. It does not produce force.

Connective tissue and collagen synthesis are stimulated by both GH and IGF-1. GH increases collagen turnover in tendons, ligaments, and the extracellular matrix surrounding muscle fibers. This connective tissue is metabolically active, contributes to lean mass measurements, and may support injury resilience over time. It does not directly contract to generate force. For athletes focused on natural GH release from exercise, the connective tissue benefits may actually be more practically meaningful than any strength effect.

Contractile protein synthesis, the growth of actin and myosin filaments within muscle fibers that generates force, appears to be less responsive to systemic GH/IGF-1 elevation than to local mechanical loading. Resistance training activates muscle-specific IGF-1 splice variants (MGF/IGF-1Ec) through mechanotransduction, a signaling pathway that systemic GH peptides do not replicate. This may explain why GH-driven lean mass gains, while real, do not translate to the strength improvements that resistance training produces.

The Sigalos and Pastuszak review summarized the state of GH secretagogue evidence: these compounds "might improve growth velocity in children, stimulate appetite, improve lean mass in wasting states and in obese individuals, decrease bone turnover, increase fat-free mass, and improve sleep," but noted that few long-term rigorous studies have examined functional strength outcomes.^[2]

What the Evidence Cannot Tell Us Yet

Several gaps in the research prevent definitive conclusions about GH peptides and strength.

No peptide-specific strength studies exist. The strength data comes from exogenous GH injection trials, not from studies using MK-677, CJC-1295, ipamorelin, or GHRP compounds specifically. GH peptides produce a different pharmacokinetic profile than injections: pulsatile rather than continuous, physiological rather than supraphysiological. Whether this pattern produces different strength outcomes remains untested.

No studies combine GH peptides with structured resistance training. The Nass et al. trial did not prescribe exercise. The Liu systematic review included studies with varying activity levels but none designed to test whether GH augments training-induced strength gains specifically. It is biologically plausible that GH peptides could enhance recovery between training sessions, support connective tissue adaptation, or improve sleep quality in ways that indirectly benefit strength development over months. Those hypotheses have not been tested.

Population matters. Most GH peptide trials enrolled elderly, obese, or GH-deficient participants. The response in young, healthy, resistance-trained individuals, the population most interested in strength enhancement, is essentially unknown. GH secretagogues in sports attract athletic populations, but the clinical evidence base does not represent them.

The dose-response relationship for strength is unexplored. GH peptides have been tested at doses optimized for GH/IGF-1 elevation, not for functional outcomes. Whether higher doses, longer durations, or combination protocols (e.g., CJC-1295 plus ipamorelin) produce strength benefits that single-peptide regimens miss is unknown.

Putting the Evidence in Context

The evidence on GH peptides and strength can be summarized in three statements, each with a different confidence level:

High confidence: GH peptides increase GH, IGF-1, and fat-free mass. Multiple RCTs across different peptide classes, populations, and durations converge on this conclusion.

High confidence: Exogenous GH elevation does not reliably increase maximal strength or power output. Systematic reviews and meta-analyses consistently show a dissociation between lean mass gains and functional performance.

Low confidence: GH peptides specifically do not improve strength. This conclusion is extrapolated from exogenous GH data, not directly tested. The pulsatile pharmacokinetics and feedback-preserved physiology of peptide-driven GH release may or may not produce different results than GH injections.

For those interested in the broader question of growth hormone and athletic performance, the disconnect between body composition and function is the central finding of the past two decades of research. The appeal of GH peptides for strength athletes rests on an assumption that has not survived contact with controlled data.

The Bottom Line

GH peptides consistently elevate growth hormone, IGF-1, and lean body mass across multiple RCTs spanning different compounds and populations. The largest and longest MK-677 trial found no strength improvement despite significant lean mass gains over two years. Systematic reviews of exogenous GH confirm this pattern: body composition changes without functional performance benefits. The lean mass gained likely includes extracellular water and connective tissue rather than purely contractile muscle protein. No trials have directly tested whether GH peptides combined with resistance training produce strength gains, leaving the most practically relevant question unanswered.

Frequently Asked Questions

Do growth hormone peptides increase muscle mass?

GH peptides like MK-677 and CJC-1295 consistently increase fat-free mass as measured by DEXA and other body composition methods. MK-677 at 25 mg/day increased fat-free mass by 1.1 kg over 12 months in healthy older adults and approximately 3 kg over 8 weeks in obese males. However, "fat-free mass" includes water, connective tissue, and organ tissue in addition to skeletal muscle, so the proportion that represents actual contractile muscle is uncertain.

Can MK-677 make you stronger?

The most rigorous MK-677 trial, a two-year double-blind RCT by Nass et al. (2008), measured isokinetic strength as an endpoint and found no improvement despite lean mass gains of 1.1 kg. The study authors explicitly stated that increased fat-free mass did not translate to changes in strength or function. No other MK-677 trial has reported positive strength outcomes.

Do GH peptides improve athletic performance?

No controlled studies have directly tested GH peptide effects on athletic performance. Evidence from exogenous GH trials in recreational athletes shows no improvement in strength or aerobic capacity, though some data suggest modest anaerobic capacity gains. GH peptides produce a different pharmacokinetic profile than injections, but whether this translates to different performance outcomes is untested.

Are GH peptides better than HGH injections for building strength?

Neither GH peptides nor exogenous HGH injections have demonstrated reliable strength improvements in controlled trials. GH peptides offer a theoretical advantage in preserving pulsatile GH secretion and normal feedback regulation, but this has not been shown to produce superior functional outcomes. Both approaches increase lean mass without clear strength benefits.

How long does it take for GH peptides to affect body composition?

Body composition changes from GH peptides appear within weeks. MK-677 increased fat-free mass measurably within 8 weeks in obese males (Svensson et al., 1998) and reversed nitrogen wasting within 7 days during caloric restriction (Murphy et al., 1998). CJC-1295 elevated IGF-1 for up to 28 days after multiple doses. Lean mass gains accumulate over months of consistent use, though the timeline for maximal response is not well defined.

What is the difference between lean mass and muscle strength?

Lean mass (or fat-free mass) includes all non-fat tissue: skeletal muscle, water, connective tissue, bone, and organs. Muscle strength is the force that contractile muscle fibers produce. GH peptides increase lean mass partly through water retention and connective tissue growth, which register on body composition scans but do not generate force. This explains why lean mass can increase while strength remains unchanged.